Does GH pay a dividend and is it safe?

Guardant Health Inc. (GH) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / GH / dividends

DGX (78) LH (74) CNC (63) ILMN (70) ⌘ Pro Terminal →

Guardant Health Inc. (GH) Dividend Safety Gauge & 10-Year DRIP Compounder

$170.73 -4.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $169.02

Guardant Health Inc. (GH) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $23.99B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Guardant Health Inc. (NASDAQ: GH) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $170.73 (-4.51% 1D, market cap $23.99B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, GH ranks #223 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GH compare to DGX and LH in the Health Care sector?

▼

Within the Health Care sector (Medical Specialities), GH carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 64.5%, and ROIC of -17.4%. By comparison, DGX (Quest Diagnostics Incorporated) holds a B+ grade (78/100 RQD, P/E 28.1x, ROIC 10.3%, cap $27.71B) and LH (Labcorp Holdings Inc.) posts a B grade (74/100 RQD, P/E 34.0x, ROIC 8.3%, cap $29.31B). Among the 5-stock peer group, DGX leads on earnings multiple (28.1x) while ILMN leads on capital efficiency (18.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GH?

▼

Per GH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001576280), Guardant Health Inc. generated $982.0M in revenue (+32.9% YoY), -$416.3M in net income, and -$233.1M in free cash flow against $2.01B in total assets and $950.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $169.02 (-1.00%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-2.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GH)Realized 20D OHLCV Swing Band: ±10%

Deterministic 5-Pillar Attribution (53/100 Composite)

🔍 WHY GH SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (34% of score)

20D Institutional Volume Accumulation (±10% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (21% of score)

Altman Z-Score 5.44 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$162.99+2.3% Next Q

Q2 (-2Q)

Grade D$166.66+9.6% Next Q

Q3 (-1Q)

Grade C-$182.59-6.5% Next Q

Current

Grade D+$170.73-0.9% Hist 90D α

Trajectory: D (45) → D+ (53)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GH currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($170.72) and Max Pain ($179.27) forces dealer call-delta covering toward $200.60.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 53%NO 47%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GH)

✓Walkthrough of GH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +87.27%📐 HORIZONTAL RANGE

2026-11-03O $185.3H $185.3L $170.7C $170.7VOL 1.50M

RES: $204.5SUP: $155.0SMA50: $170.7SMA200: $131.6

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GH Butterfly Map → + Track GH →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

12.4%/yr Implied 5Y Growth

vs. +32.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GH)

Health Care Rank #223 of 1015 ⚔️ DGX vs GH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GH vs. DGX, LH, CNC, ILMN)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Guardant Health Inc. (GH) ranks #223 by composite RQD confidence (53/100, grade D+) and #65 by equity capitalization ($23.99B). Within this direct 5-issuer industry benchmark cohort, DGX leads on earnings valuation at 28.1x trailing P/E, while ILMN leads on capital efficiency and profitability with 18.2% ROIC and 66.1% gross margin. DGX currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with GH at 53/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GH ACTIVE Guardant Health Inc.	D+	53/100	—	64.5%	-17.4%	-4.51%	$23.99B	Benchmark Subject
DGX Quest Diagnostics Incorporated	B+	78/100	28.1x	33.2%	10.3%	-0.40%	$27.71B	/dgx-vs-gh →
LH Labcorp Holdings Inc.	B	74/100	34.0x	28.8%	8.3%	-1.60%	$29.31B	/lh-vs-gh →
CNC Centene Corporation	C	63/100	—	8.1%	-31.0%	-2.80%	$33.89B	/cnc-vs-gh →
ILMN Illumina Inc.	B-	70/100	51.5x	66.1%	18.2%	-3.99%	$35.63B	/ilmn-vs-gh →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001576280 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Guardant Health Inc. (GH) reported GAAP revenue of $982.0M (+32.9% vs. FY2024 revenue of $739.0M , and +74.1% cumulative change since FY2023) , GAAP net income of -$416.3M, operating cash flow of -$184.8M, and free cash flow of -$233.1M (+15.2% YoY). On the balance sheet, GH closed FY2025 with $2.01B in total assets against $950.8M in total debt (Altman Z-Score: 5.44, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$982.0M	-$416.3M	-$184.8M	-$233.1M	$2.01B	$950.8M
FY2024 (FY)	2024-12-31	$739.0M	-$436.4M	-$239.9M	-$274.9M	$1.49B	$731.4M
FY2023 (FY)	2023-12-31	$563.9M	-$479.4M	-$325.0M	-$350.4M	$13.68B	$3.20B

3. GH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GH compare to DGX and LH in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for GH?

Where is GH trading relative to its 50-day, 200-day, and 52-week technical levels?

GH last traded at $170.73 (-4.51% on volume of 2,390,124 shares), positioning the stock +0.01% above its 50-day simple moving average ($170.72) and +29.78% above its 200-day simple moving average ($131.55). Across its 52-week range of $74.55 to $191.05, GH sits at the 82.6% percentile with a 14-day RSI of 54.9 (NEUTRAL RANGE) and an implied next-earnings move of ±10.0% ($153.66 to $187.80).

Direct Sub-Reports: GH RQD Cockpit GH 12M Forecast GH Earnings & Move GH Dividends & DRIP GH Insiders & 13F GH Whale Options GH Profit Sankey GH News & Why

ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ SEC XBRL & RQD VERIFIED

GH — Guardant Health Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Guardant Health Inc. (GH) earns a live Roarable RQD composite score of 53/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $170.73 (-4.51% 1D, market capitalization $23.99B).

Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -17.4%, gross margin of 64.5%, operating margin of -44.5%, and free cash flow yield of -0.94%.
Whale 13F & Options Flow (18/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (11/20): Incorporates a 0.87x equity beta, Altman Z-Score of 5.44, Piotroski F-Score of 6/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Guardant Health Inc. (GH) is a NASDAQ-listed issuer in the Health Care sector, Medical Specialities industry. The company has a market capitalization of $24.9B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Guardant Health Inc. (GH) reported $982.0M in annual revenue (up from $739.0M in FY2024, +32.9% YoY) and -$416.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($563.9M revenue, -$479.4M net income) through FY2025, GH scaled operating cash flow to -$184.8M and free cash flow to -$233.1M, backed by $2.01B in total assets against $950.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D+ • RQD 53/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -0.94% and institutional whale pillar of 18/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $74.55 – $191.05 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -44.5% operating margins and a 0.87x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical Specialities (Health Care), GH carries a macro regime beta of 0.87 and gross margin of 64.5%.

Key Question #1: Can GH sustain or expand its -44.5% operating margin and -17.4% ROIC against Medical Specialities peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $982.0M and free cash flow of -$233.1M, how will capital allocation balance growth reinvestment against $950.8M in total debt?
Key Question #3: How sensitive is GH's 19.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.87x)?

GH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Guardant Health Inc. (GH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GH Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Guardant Health, Inc. (GH) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know

TradingKey report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 1d ago

Guardant Health: Growth Remains Too Expensive, Reiterate Hold (NASDAQ:GH)

Seeking Alpha report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Singapore • 1d ago

Guardant Health, Inc. (GH) stock price, news, quote and history

Yahoo Finance Singapore report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE FXEmpire • 1d ago

Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250

FXEmpire report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A blood test in Europe can help identify who may benefit from AstraZeneca’s breast cancer drug

Stock Titan report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH FinancialContent • 1d ago

3 Reasons GH is risky and 1 stock to buy instead

FinancialContent report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Guardant Health (GH) Stock Looks Rich Even With Cash Flow Upside

Simply Wall St report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GH Bull vs. Bear Conversation Board — What's Your Call at $170.73?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GH 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $225.29 (+26.0%)

📌 Pinned Debate

Institutional accumulation and options positioning score 18/20 in the RQD rating, the strongest pillar.

Long GH at $178.80 targeting $225.29. Institutional accumulation and options positioning score 18/20 in the RQD rating, the strongest pillar.. Institutional whale score is 18/20 and the risk/reward vs. the $74.55 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

@RedlineAuditor Shorting a 18/20 institutional whale-flow stock at $178.80 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $150.19 (-16.0%)

Spot @ $178.80

ROIC of -17.4% and FCF yield of -0.94% leave the fundamental cash engine at 9/20 despite $982.0M revenue.

Sitting on the sidelines or leaning short GH above $178.80. ROIC of -17.4% and FCF yield of -0.94% leave the fundamental cash engine at 9/20 despite $982.0M revenue.. Until Fundamental Cash Engine (9/20) and FCF yield (-0.94%) inflect higher, upside is capped near $191.05.